ARS Pharmaceuticals (SPRY) Interest Expenses (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Interest Expenses data on file, last reported at $35.6 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 323218.18% year-over-year to $35.6 million; the trailing twelve-month figure through Mar 2026 stood at $35.6 million (up 323218.18% YoY), and the FY2025 full-year result was $78.2 million, up 9.32% from the prior year.
• Interest Expenses advanced to $35.6 million in Q1 2026, from $2.3 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $39.4 billion in Q1 2023 to a low of -$184000.0 in Q4 2024.
• A 5-year average of $5.8 billion and a median of $43.8 million in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses soared 875193.2% in 2023 and plunged 99.99% in 2025, its largest moves.
• Tracing SPRY's Interest Expenses over 5 years: stood at $100000.0 in 2022, then surged by 15442325.0% to $15.4 billion in 2023, then slumped by 100.0% to -$184000.0 in 2024, then jumped by 1367.39% to $2.3 million in 2025, then surged by 1425.09% to $35.6 million in 2026.
• Business Quant data shows SPRY's Interest Expenses at $35.6 million in Q1 2026, $2.3 million in Q4 2025, and $59.8 million in Q3 2025.